The manuscript entitled “Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20+ Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical models” was recently published in the Haematologica journal (IF=10.1).
It is the result of cooperation between the team of Małgorzata Firczuk, PhD from the Department of Immunology MMRI PAS and research groups from the Medical University of Lodz, the Institute of Hematology and Transfusion Medicine in Warsaw, and the Medical University of Silesia. The first author of the paper is a PhD student of MMRI PAS, Krzysztof Domka. Haematologica, founded in 1920, is one of the most prestigious journals in the field of hematology, publishing the results of clinical trials and preclinical studies of clinical importance.
The manuscript presents preclinical studies on the effectiveness of combination therapies in the treatment of acute lymphoblastic leukemia with the Philadelphia chromosome. The study assessed the efficacy of different combinations of tyrosine kinase inhibitors (TKIs) and monoclonal antibodies directed against the CD20 protein. TKIs were observed to reduce the amount of CD20 on leukemic cells, which may reduce the efficacy of anti-CD20 antibodies. In addition, individual TKIs were shown to have different effects on immune cells, such as NK cells and macrophages, which are responsible for the efficacy of monoclonal antibodies. The next-generation TKI, asciminib, has emerged as the most promising drug, as it does not inhibit immune cell function, allowing optimal anti-leukemic activity of anti-CD20 antibodies. These findings may be crucial for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, suggesting the need for precise selection of TKIs for combination therapy with monoclonal antibodies. By proposing a new therapeutic combination, the study indicates potential opportunities to improve the efficacy of treatment for this aggressive form of leukemia.
https://doi.org/10.3324/haematol.2023.284853
 
Haematologica logo cut

 

We cordially invite you to participate in the Symposium.

FREE Admission to all sessions!

Online registration - CLICK HERE

Agenda in PDF for download: CLICK HERE

POL AM symposium str 1

 

POL AM symposium final str 2 v2

 

Researchers from MMRI PAS awarded funding in National Science Centre OPUS 26 and SONATA 19 calls!

Opus logo wycięteOPUS 26

Agnieszka Graczyk-Jarzynka PhD, Department of Immunology
"Modulation of the N-glycosylation as a tool to improve the CAR-T immunotherapy efficacy"

Izabela Sabała PhD, Head of the Laboratory of Protein Engenering
"Activation of Staphylococcus aureus LytM autolysin as a potential target for antimicrobials development"

Michał Węgrzynowicz PhD, Head of the Laboratory of Molecular Basis of Neurodegeneration
"Importance of mitochondrial calcium uniporter for unique resistance of CA2 hippocampal neurons to injury"

Sonata logo wycięte  SONATA 19

Mariusz Popek PhD, Department of Neurotoxicology
"New insight into the mechanism of cytotoxic brain edema in acute liver failure: focus on the functionality of mitochondria"

Congratulations!

 

 

 

Congratulations to researchers from our Institute who obtained funding
in National Science Center calls!

  Granty NCN czerwiec 2024 www ENG

 

On May 13 - 15, we participated in the 15th National Conference of Polish Association of Centers for Technology Transfer (PACTT.pl) in Puławy/Kazimierz Dolny.
The conference was an opportunity to exchange experiences, discuss commercialization, and meet representatives of Technology Transfer Centers, patent attorneys and investors. During three days of the conference, interesting topics were discussed, among others: issues of new regulations related to intellectual property, challenges of cooperation between science and the economic environment or the use of research infrastructure to implement R&D projects.

 Konferencja PACTT

  1. Congratulations-Aleksandra Kaczyńska
  2. Symposium - invitation
  3. Cancer Fight Research Club-spring 2024
  4. Happy Easter!